More Videos
SPECIAL REPORT
MOST SHARED
- Kohlberg Kravis Bidding for Morgan Stanley's CICC Stake
- Cisco Has 84% of Tandberg, Won't Extend Bid
- Case Closed but Woods Scrutiny Continues
- UK Economy Turned, Inflation to Spike: BoE Economist
- Keeping America Great
- Australia Regulator Opposes Caltex-Exxon Deal
- GE, Comcast Complete Deal Over NBC Universal: Source
- Toyota Takes Lead Position in Canada in November
- Treasury Assistance Comes at High Price For GM
- Unemployment to Peak at 10.5%: Moody's Economist
- 8 Stocks to Gain on Obama's Afghan Plan: Analysts
- BofA On Proposed Changes In The Housing Bailout Program
- The Future of The Media Landscape
- November Auto Sales Muddle Along
- Busch: What Obama Won't Say Tonight
- Stick with Equities—Avoid Emerging Markets: Laszlo Birinyi
- Pfizer Chomps On A Carrot
- Mortgage Applications Up; Rates Hit 6- Month High
- Wal-Mart Targets Video Games with Latest Price Cuts
- 'Black Swan' Shuns Public Life Because of Bernanke
- Dubai World To Meet with Creditors Next Week
- FHA to Toughen Mortgage Rules in Lenders Crackdown
- Obama to Send More Troops; Seeks Afghanistan Exit
- GM Removes CEO Henderson; Whitacre Is Interim Chief
- UK Economy Turned, Inflation to Spike: BoE Economist
- Who Were the Biggest Winners And Losers This Year?
PHARMA'S MARKET VIDEO
RSS FEED
Pharma's Market
Text Size 
 |
Not to mention the significance of an upgrade or a downgrade. But as equity research departments are being downsized or eliminated, it looks like a lot of biopharma coverage might be falling by the wayside.
The folks on Team Biopharma at Thomson Reuters keep track of analyst comings and goings. This week alone at least three firms have "dropped" coverage of the sector. Biotech analyst Jim Reddoch has left FBR and the firm suspended coverage of all but one of the companies he covered. Then this morning, in their daily sector pulse note to clients, TR says George Farmer is leaving Wachovia which is suspending coverage of the 18 biotech companies he looked after.
And also according to TR, Broadpoint Capital is "dropping coverage of the Biotechnology sector due to the departure of the covering analysts." That reportedly includes 17 ticker symbols. "Suspending", of course, is a key word, though. Certainly it's possible the firms will replace the analysts who will resume coverage. But lately, generally speaking, it seems less likely.
And that's just the tip of the iceberg. From big Wall Street firms to boutique houses, from big pharma to baby biotechs, from medical devices to healthcare services, TR points out that over the past several months there's been a flurry of analyst departures, layoffs and suspensions, drops, transitions and reviews of analyst coverage. Way too many, frankly, to list here. But not everyone's ending up on the unemployment line. TR says several former Bear Stearns analysts, for example, are popping up all over the Street.
Mark Schoenebaum, who used to be at BS, is now at Deutsche Bank. Yesterday, I listened into a pre-earnings season conference call he did for clients during which he discussed, among other things, what Amgen [AMGN
Loading...
()
]might be worth in a takeout. He estimates that if an acquirer could cut out 25 percent of costs in synergies that AMGN might be worth as much as $62 a share. "Who might buy Amgen?" Schoenebaum asked. "Give Barbara Ryan (DB's pharma analyst) a call," he said. Ryan's been saying for months that Pfizer [PFE
Loading...
()
]should buy Amgen.
DB makes a market in PFE & AMGN and owns at least one percent of the shares. It would also like to do investment banking for PFE. Pfizer Chairman and CEO Jeff Kindler and his senior management have consistently said they're not interested in doing a big deal. Meantime, PFE's market cap has fallen to number three in big pharma behind Novartis[NVS
Loading...
()
] and GlaxoSmithKline[GSK
Loading...
()
]. Johnson & Johnson's [JNJ
Loading...
()
]market cap dwarfs them all, but it's not really a drug pure-play.
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes